Glurenorm

Glurenorm is a prescription oral medication that contains the sulfonylurea gliquidone as its active ingredient. It is supplied in tablet form for systemic use and is marketed in the European Union. As a member of the sulfonylurea class, Glurenorm works by stimulating insulin release from pancreatic beta cells, helping to lower elevated blood glucose levels in patients with type 2 diabetes mellitus and is typically prescribed by healthcare professionals.

Glurenorm is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient.

- As monotherapy in patients newly diagnosed with type 2 diabetes. - In combination with metformin when glycemic control is not achieved with metformin alone. - As adjunct to other oral antidiabetic agents such as thiazolidinediones. - For patients who have demonstrated adequate pancreatic beta‑cell function. - To assist in achieving individualized HbA1c targets as part of a comprehensive diabetes care plan.

The safety profile of Glurenorm includes a range of observed adverse reactions, which are generally categorized by frequency and severity.

Common: - Mild hypoglycemia, especially when meals are skipped or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Skin reactions like rash or pruritus. - Headache or dizziness.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including angioedema or anaphylaxis. - Hepatotoxicity manifested by jaundice or elevated liver enzymes. - Hematologic abnormalities such as leukopenia or thrombocytopenia.

Before initiating Glurenorm, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function, as impairment may increase drug exposure. - Verify that the patient has sufficient endogenous insulin production. - Use caution in elderly patients due to heightened hypoglycemia risk. - Review history of cardiovascular disease, as sulfonylureas may affect cardiac outcomes. - Counsel patients on recognizing and managing hypoglycemia symptoms. - Avoid use during pregnancy and lactation unless benefits outweigh risks.

Glurenorm can interact with other medicines, potentially altering its glucose‑lowering effect or increasing adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone plasma levels.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can impair glucose control. - Anticoagulants such as warfarin, as glycemic changes may affect INR stability. - NSAIDs, which may affect renal function and drug clearance.